Divis Lab Shares
- All
- News
- Videos
-
Divi's Labs Shares Decline Over 6% After Q4 Earnings
Shares of Divi's Laboratories fell more than 6 per cent on Tuesday as the company's March quarter earnings failed to cheer investors. The stock dropped as much as 6.35 per cent to hit an intraday low of Rs 3,650.
-
Nifty Seen Opening Near 18,000; Sun TV, Divi's Labs In Focus
Foreign institutional investors sold shares worth Rs 328 crore on Thursday while domestic institutional investors bought shares worth Rs 38 crore.
-
Divi's Labs Surges 10%, Hits Record High On Merck's Positive Data For Covid Drug
Divi's Laboratories shares have so far this year advanced 38 per cent compared with Sensex which has gained 25 per cent.
-
UltraTech Cement, TCS, Divi's Labs Among Anand Rathi's Top Diwali Picks
The benchmarks have staged a strong rally from the lows hit in March as the country went into lockdown to curb the spread of COVID-19 pandemic.
-
Divi's Labs Surges 16% To Hit New 52-Week High On Strong Earnings
Divi's Labs shares have surged 125 per cent since August 14, the day it hit a 52-week low of Rs 1,466.
-
Divi's Lab Shares Pare Gains, Trade Flat After US FDA Closes Out Warning Letter
The shares of Divi's Laboratories (Divi's Lab) pared early gains to trade 0.86% higher at Rs 1,018 on BSE at 3.10 pm. The scrip had hit 8% higher
-
Divi's Lab Shares Close 17% Higher As USFDA's Import Ban Set To Be Lifted From Vizag Plant
Divi's Laboratories has informed the NSE in a stock exchange filing that the USFDA will soon lift the import Alert 66-40 and will move to close out the warning letter issued to the company's unit-II at Vishakhapatnam.
-
US Bans Divi's Factory, Shares Hit 3-Year Low
The FDA has banned more than 40 Indian factories in recent years over quality control failures and manipulation of data.
-
Sensex Ends Flat For Third Day, Pharma Shares Fall
Analysts expect a period of consolidation ahead as investors focus on individual stock movements as they wait for the earnings season to start in mid-April.
-
Divis Lab Slumps 20% After US Regulator Issues Import Alert For Vizag Plant
Surjit Pal, pharma analyst at Prabhudas Lilladher, says Divis Lab shares could remain under pressure as its FY18 earnings would be hit due to the import alert.
-
Divi's Laboratories Files Response To US Regulator's Observations
Last month, the US regulator had made five observations after inspection of the company's manufacturing plant at Visakhapatnam.
-
Buy Kotak Bank, Fortis Healthcare; Sell Divi's Labs: Sameet Chavan
Nifty took a breather after rallying from lows of 7,893 and now Nifty has important support around 8,180-8,200 levels, says Sameet Chavan, equity technical analyst with Angel Broking.
-
Nifty Hovers Around 7,900, Metal Stocks Under Pressure
Pharma and metal shares were the worst hit in trade today. The metal and pharma sub-indices of NSE were down 1.5 and 1.6 per cent respectively.
-
Divi's Labs Slumps 6% After FDA Observations On Vizag Facility
The company said Unit-II at Visakhapatnam, Andhra Pradesh, has had an inspection by the US Food and Drug Administration (USFDA) from November 29 to December 6.
-
Divis Laboratories Announces Rs 80 Crore Bonanza For Employees
Divis Laboratories said that the special payment of Rs 79 crore will be reflected in its September quarter numbers.
-
Divi's Labs Shares Decline Over 6% After Q4 Earnings
Shares of Divi's Laboratories fell more than 6 per cent on Tuesday as the company's March quarter earnings failed to cheer investors. The stock dropped as much as 6.35 per cent to hit an intraday low of Rs 3,650.
-
Nifty Seen Opening Near 18,000; Sun TV, Divi's Labs In Focus
Foreign institutional investors sold shares worth Rs 328 crore on Thursday while domestic institutional investors bought shares worth Rs 38 crore.
-
Divi's Labs Surges 10%, Hits Record High On Merck's Positive Data For Covid Drug
Divi's Laboratories shares have so far this year advanced 38 per cent compared with Sensex which has gained 25 per cent.
-
UltraTech Cement, TCS, Divi's Labs Among Anand Rathi's Top Diwali Picks
The benchmarks have staged a strong rally from the lows hit in March as the country went into lockdown to curb the spread of COVID-19 pandemic.
-
Divi's Labs Surges 16% To Hit New 52-Week High On Strong Earnings
Divi's Labs shares have surged 125 per cent since August 14, the day it hit a 52-week low of Rs 1,466.
-
Divi's Lab Shares Pare Gains, Trade Flat After US FDA Closes Out Warning Letter
The shares of Divi's Laboratories (Divi's Lab) pared early gains to trade 0.86% higher at Rs 1,018 on BSE at 3.10 pm. The scrip had hit 8% higher
-
Divi's Lab Shares Close 17% Higher As USFDA's Import Ban Set To Be Lifted From Vizag Plant
Divi's Laboratories has informed the NSE in a stock exchange filing that the USFDA will soon lift the import Alert 66-40 and will move to close out the warning letter issued to the company's unit-II at Vishakhapatnam.
-
US Bans Divi's Factory, Shares Hit 3-Year Low
The FDA has banned more than 40 Indian factories in recent years over quality control failures and manipulation of data.
-
Sensex Ends Flat For Third Day, Pharma Shares Fall
Analysts expect a period of consolidation ahead as investors focus on individual stock movements as they wait for the earnings season to start in mid-April.
-
Divis Lab Slumps 20% After US Regulator Issues Import Alert For Vizag Plant
Surjit Pal, pharma analyst at Prabhudas Lilladher, says Divis Lab shares could remain under pressure as its FY18 earnings would be hit due to the import alert.
-
Divi's Laboratories Files Response To US Regulator's Observations
Last month, the US regulator had made five observations after inspection of the company's manufacturing plant at Visakhapatnam.
-
Buy Kotak Bank, Fortis Healthcare; Sell Divi's Labs: Sameet Chavan
Nifty took a breather after rallying from lows of 7,893 and now Nifty has important support around 8,180-8,200 levels, says Sameet Chavan, equity technical analyst with Angel Broking.
-
Nifty Hovers Around 7,900, Metal Stocks Under Pressure
Pharma and metal shares were the worst hit in trade today. The metal and pharma sub-indices of NSE were down 1.5 and 1.6 per cent respectively.
-
Divi's Labs Slumps 6% After FDA Observations On Vizag Facility
The company said Unit-II at Visakhapatnam, Andhra Pradesh, has had an inspection by the US Food and Drug Administration (USFDA) from November 29 to December 6.
-
Divis Laboratories Announces Rs 80 Crore Bonanza For Employees
Divis Laboratories said that the special payment of Rs 79 crore will be reflected in its September quarter numbers.
